TTR and alpha 1-antitrypsin deficiency: In addition to therapeutics development to treat AATD in liver, non-viral, lipid nanoparticle (LNP) delivery of Cas9 facilitating hepatocyte selective targeting for the editing of mouse liver transthyretin gene, the mouse homolog of the human gene associated with Transthyretin Amyloidosis, which is caused by a buildup of misfolded transthyretin protein [126].